Recent News

• 12.11.2025 - Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology
• 12.09.2025 - Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis
• 11.25.2025 - Bio-Techne to Present at Upcoming Investor Conferences
• 11.18.2025 - Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio
• 11.06.2025 - Bio-Techne to Present at Upcoming Investor Conferences
• 11.05.2025 - 10-Q - Quarterly report [Sections 13 or 15(d)]
• 11.05.2025 - BIO-TECHNE DECLARES DIVIDEND
• 11.05.2025 - Bio-Techne Releases First Quarter Fiscal 2026 Results
• 11.04.2025 - AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients
• 11.03.2025 - ScaleReady Announces a G-Rex® Grant has been awarded to Sonoma Biotherapeutics

Recent Filings

• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.05.2025 - 8-K Current report
• 11.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.05.2025 - EX-99.1 EX-99.1
• 11.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.03.2025 - 4 Statement of changes in beneficial ownership of securities